It is used in the therapy of HER2-positive breast cancer as an associated therapy in combination with anthracycline or taxane-based chemotherapy and in metastatic, HER2-positive, breast cancer as a monotherapy or associated with paclitaxel. Here, ERBB2 is linked to breast cancer.